Log in

NASDAQ:SCYXSCYNEXIS News Headlines

$0.71
-0.01 (-1.39 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.68
Now: $0.71
$0.72
50-Day Range
$0.72
MA: $0.79
$0.89
52-Week Range
$0.50
Now: $0.71
$1.44
Volume706,800 shs
Average Volume551,281 shs
Market Capitalization$70.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77

Headlines

SCYNEXIS (NASDAQ SCYX) News Headlines

Source:
DateHeadline
-$0.11 Earnings Per Share Expected for SCYNEXIS Inc (NASDAQ:SCYX) This Quarter-$0.11 Earnings Per Share Expected for SCYNEXIS Inc (NASDAQ:SCYX) This Quarter
www.americanbankingnews.com - July 9 at 4:18 PM
SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections - GlobeNewswireSCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections - GlobeNewswire
www.globenewswire.com - July 9 at 1:02 PM
SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast InfectionsSCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections
finance.yahoo.com - July 9 at 1:02 PM
SCYNEXIS Inc (NASDAQ:SCYX) Receives Consensus Recommendation of "Buy" from BrokeragesSCYNEXIS Inc (NASDAQ:SCYX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 18 at 2:38 AM
 Analysts Expect SCYNEXIS Inc (NASDAQ:SCYX) Will Post Earnings of -$0.11 Per Share Analysts Expect SCYNEXIS Inc (NASDAQ:SCYX) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - June 17 at 11:12 AM
SCYNEXIS to Present at the BIO Digital International Convention 2020 - GlobeNewswireSCYNEXIS to Present at the BIO Digital International Convention 2020 - GlobeNewswire
www.globenewswire.com - June 8 at 6:07 PM
SCYNEXIS to Present at the BIO Digital International Convention 2020SCYNEXIS to Present at the BIO Digital International Convention 2020
finance.yahoo.com - June 8 at 12:57 PM
SCYNEXIS Inc (SCYX): Are Hedge Funds Right About This Stock? - Yahoo FinanceSCYNEXIS Inc (SCYX): Are Hedge Funds Right About This Stock? - Yahoo Finance
finance.yahoo.com - June 4 at 11:08 PM
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales - GlobeNewswireSCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales - GlobeNewswire
www.globenewswire.com - June 2 at 1:25 PM
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and SalesSCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales
finance.yahoo.com - June 2 at 1:25 PM
3 ‘Strong Buy’ Biotech Stocks Under $5 That Could Go Boom - Nasdaq3 ‘Strong Buy’ Biotech Stocks Under $5 That Could Go Boom - Nasdaq
www.nasdaq.com - June 1 at 2:32 PM
Scynexis: 1Q Earnings Snapshot - Yahoo FinanceScynexis: 1Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - May 12 at 2:24 AM
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update - GlobeNewswireSCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update - GlobeNewswire
www.globenewswire.com - May 11 at 9:24 PM
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company UpdateSCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
finance.yahoo.com - May 11 at 4:19 PM
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp - GlobeNewswireSCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp - GlobeNewswire
www.globenewswire.com - May 6 at 1:01 PM
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of IbrexafungerpSCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
finance.yahoo.com - May 6 at 1:01 PM
SCYNEXIS, Inc. S-3 May. 1, 2020 4:01 PM - Seeking AlphaSCYNEXIS, Inc. S-3 May. 1, 2020 4:01 PM - Seeking Alpha
seekingalpha.com - May 2 at 10:10 AM
BRIEF-Scynexis Inc Files For Offering Of Up To 19.4 Million Shares Of Common Stock By Selling Stockholder - SEC Filing - ReutersBRIEF-Scynexis Inc Files For Offering Of Up To 19.4 Million Shares Of Common Stock By Selling Stockholder - SEC Filing - Reuters
www.reuters.com - May 1 at 7:07 PM
SCYNEXIS to Participate in Antifungals Panel at Maxim Groups Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector - GlobeNewswireSCYNEXIS to Participate in Antifungals Panel at Maxim Group's Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector - GlobeNewswire
www.globenewswire.com - April 29 at 4:28 AM
SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector - Yahoo FinanceSCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector - Yahoo Finance
finance.yahoo.com - April 28 at 8:25 AM
SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective SectorSCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
finance.yahoo.com - April 28 at 8:25 AM
How Does SCYNEXIS, Inc. (NASDAQ:SCYX) Affect Your Portfolio Volatility? - Yahoo Finance UKHow Does SCYNEXIS, Inc. (NASDAQ:SCYX) Affect Your Portfolio Volatility? - Yahoo Finance UK
uk.finance.yahoo.com - April 27 at 10:24 PM
How Does SCYNEXIS, Inc. (NASDAQ:SCYX) Affect Your Portfolio Volatility?How Does SCYNEXIS, Inc. (NASDAQ:SCYX) Affect Your Portfolio Volatility?
finance.yahoo.com - April 27 at 5:23 PM
BRIEF-Scynexis Says Ibrexafungerp Was Generally Safe And Well-Tolerated - ReutersBRIEF-Scynexis Says Ibrexafungerp Was Generally Safe And Well-Tolerated - Reuters
www.reuters.com - April 21 at 8:44 AM
Scynexis up 20% premarket on second positive study of ibrexafungerp - Seeking AlphaScynexis up 20% premarket on second positive study of ibrexafungerp - Seeking Alpha
seekingalpha.com - April 21 at 8:44 AM
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
finance.yahoo.com - April 21 at 8:44 AM
Scynexis closes $20M stock purchase deal - Seeking AlphaScynexis closes $20M stock purchase deal - Seeking Alpha
seekingalpha.com - April 13 at 11:07 PM
BRIEF-Scynexis, Aspire Capital Enter $20 Mln Common Stock Purchase Agreement - ReutersBRIEF-Scynexis, Aspire Capital Enter $20 Mln Common Stock Purchase Agreement - Reuters
www.reuters.com - April 13 at 1:06 PM
Form 8-K SCYNEXIS INC For: Apr 10 - StreetInsider.comForm 8-K SCYNEXIS INC For: Apr 10 - StreetInsider.com
www.streetinsider.com - April 13 at 1:06 PM
SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement - GlobeNewswireSCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement - GlobeNewswire
www.globenewswire.com - April 13 at 1:06 PM
SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase AgreementSCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement
finance.yahoo.com - April 13 at 1:06 PM
Scynexis shores up finances with $10M convertible debt deal - Seeking AlphaScynexis shores up finances with $10M convertible debt deal - Seeking Alpha
seekingalpha.com - April 9 at 2:49 PM
SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital - Yahoo FinanceSCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital - Yahoo Finance
finance.yahoo.com - April 9 at 9:49 AM
SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance CapitalSCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital
finance.yahoo.com - April 9 at 9:48 AM
SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 - GlobeNewswireSCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 - GlobeNewswire
www.globenewswire.com - March 26 at 2:07 PM
SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 - Yahoo FinanceSCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 - Yahoo Finance
finance.yahoo.com - March 26 at 9:07 AM
SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020
finance.yahoo.com - March 26 at 9:07 AM
Earnings Update: SCYNEXIS, Inc. Just Reported And Analysts Are Boosting Their Estimates - Yahoo FinanceEarnings Update: SCYNEXIS, Inc. Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
finance.yahoo.com - March 13 at 9:28 PM
Earnings Update: SCYNEXIS, Inc. Just Reported And Analysts Are Boosting Their EstimatesEarnings Update: SCYNEXIS, Inc. Just Reported And Analysts Are Boosting Their Estimates
finance.yahoo.com - March 13 at 4:27 PM
SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update - GlobeNewswireSCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update - GlobeNewswire
www.globenewswire.com - March 11 at 8:30 AM
SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company UpdateSCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
finance.yahoo.com - March 11 at 8:30 AM
BRIEF-SCYNEXIS Announces Preclinical Data On Ibrexafungerp And Azoles Against Aspergillus Presented At The 9Th Advances Against Aspergillosis And Mucormycosis Conference - ReutersBRIEF-SCYNEXIS Announces Preclinical Data On Ibrexafungerp And Azoles Against Aspergillus Presented At The 9Th Advances Against Aspergillosis And Mucormycosis Conference - Reuters
www.reuters.com - March 5 at 2:04 PM
Scynexis (SCYX) Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at Conference - StreetInsider.comScynexis (SCYX) Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at Conference - StreetInsider.com
www.streetinsider.com - March 5 at 9:03 AM
SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference - Yahoo FinanceSCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference - Yahoo Finance
finance.yahoo.com - March 5 at 9:03 AM
SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis ConferenceSCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference
finance.yahoo.com - March 5 at 9:03 AM
SCYNEXIS, Inc. Common Stock (SCYX) Revenue EPSSCYNEXIS, Inc. Common Stock (SCYX) Revenue EPS
www.nasdaq.com - February 24 at 12:04 AM
BRIEF-Scynexis Completes Patient Enrollment In Study Of Vaginal Yeast Infection TreatmentBRIEF-Scynexis Completes Patient Enrollment In Study Of Vaginal Yeast Infection Treatment
www.msn.com - February 15 at 12:54 AM
Form SC 13G/A SCYNEXIS INC Filed by: CAXTON CORP - StreetInsider.comForm SC 13G/A SCYNEXIS INC Filed by: CAXTON CORP - StreetInsider.com
www.streetinsider.com - February 14 at 7:53 PM
BRIEF-Scynexis Completes Patient Enrollment In Study Of Vaginal Yeast Infection Treatment - ReutersBRIEF-Scynexis Completes Patient Enrollment In Study Of Vaginal Yeast Infection Treatment - Reuters
www.reuters.com - February 13 at 12:14 PM
Scynexis completes enrollment in second pivotal study of ibrexafungerp - Seeking AlphaScynexis completes enrollment in second pivotal study of ibrexafungerp - Seeking Alpha
seekingalpha.com - February 13 at 12:14 PM
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.